Mylotarg (Gemtuzumab Ozogamicin)

Gemtuzumab ozogamicin is an antibody‑drug conjugate that binds to the CD33 antigen on myeloid leukemia cells. After binding, the complex is internalized and releases calicheamicin, a potent DNA‑cleaving agent. The resulting double‑strand DNA breaks trigger apoptosis, selectively eliminating CD33‑expressing malignant cells.

The dosing regimen for Mylotarg is individualized by the prescribing physician based on the patient’s age, disease status, body surface area, and treatment protocol. Clinicians calculate the appropriate dose and schedule according to the latest clinical guidelines and product labeling.

Mylotarg is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Breastfeeding is not recommended while receiving treatment, as the drug may be excreted in milk.

To order Mylotarg, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Mylotarg is a CD33‑targeted antibody‑drug conjugate, offering a mechanism distinct from conventional cytotoxic chemotherapy. Compared with standard chemotherapy alone, Mylotarg can improve remission rates in CD33‑positive AML when added to treatment regimens. Unlike some newer small‑molecule inhibitors, it delivers a cytotoxic payload directly to leukemic cells, which may reduce off‑target toxicity but requires careful monitoring for liver‑related adverse events.

Mylotarg should be stored refrigerated at 2‑8 °C. The lyophilized powder must be protected from light, must not be frozen, and should not be shaken. Before administration, reconstitute according to the product label in a sterile environment and use within the time frame specified by the manufacturer.

Mylotarg is administered by intravenous infusion. After reconstitution of the lyophilized powder with the appropriate diluent, the solution is infused over a prescribed period, typically under close medical supervision to monitor for infusion‑related reactions and other adverse effects.

The most serious risks associated with Mylotarg include veno‑occlusive disease (VOD) of the liver, severe bleeding events, and anaphylactic or severe allergic reactions. Early detection of liver dysfunction, careful monitoring of coagulation parameters, and readiness to manage hypersensitivity reactions are essential during therapy.

Mylotarg is contraindicated in patients with known hypersensitivity to gemtuzumab ozogamicin or any component of the formulation. It should also be avoided in individuals with severe pre‑existing liver disease, uncontrolled active infections, or those who are pregnant without a clear benefit‑risk justification. Clinicians must assess each patient’s medical history before initiating therapy.